Lumenis Acquires Pollogen and Expands its Aesthetic Division

Lumenis Ltd. completed its acquisition of Pollogen Ltd., an Israeli-based medical aesthetic company that develops and manufactures advanced technologies with full-lines of clinically proven, non-invasive, anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applications. The product platforms include OxyGeneo®, VoluDerm™, Hybrid Energy™, TriPollar®, TriLipo® and TriFractional™.  Pollogen will strengthen Lumenis’ position in the beauty segment with its advanced solutions with a focus on radio-frequency technology.

“We are excited to welcome the Pollogen team into the Lumenis family,” said Tzipi Ozer-Armon, CEO of Lumenis. “This transaction complements our aesthetic product portfolio and positions Lumenis well in the dynamic beauty market. The addition of Pollogen’s extensive portfolio is key to continuing to provide tailored and innovative beauty solutions to all of our existing and future aesthetic customers.”

“This transaction is a positive outcome for our shareholders, employees and customers,” said Zion Azar, co-founder and Chairman of Pollogen. “Over the past 10 years, Pollogen has built a leading position in the aesthetic beauty market based on a culture of innovation and pioneering research. We are thrilled to join the Lumenis team and further develop our products and presence in this rapidly developing market.”